Gnosis by Lesaffre has announced its entry into the private label sector with the new MenaQ7 Protect, a stick pack for daily and long-term optimised immune support. Created in collaboration with Probiotical, MenaQ7 Protect offers a seamless ready-to-market solution that addresses the needs of the increasingly quality-conscious and on-the-go consumer.
Each MenaQ7 Protect stick pack provides 1 billion cells each of Bifidobacterium animalis subsp. lactis BS01 (LMG-P-21384), Lacticaseibacillus rhamnosus LR04 (DSM 16605), and Bifidobacterium bifidum BB10 (DSM 33678) – strains all carefully selected for their immune-supporting benefits – with 75 mcg of MenaQ7 Vitamin K2 as MK-7, and 80 mg vitamin C. The product is available in a tangy orange flavor and may be ingested directly or added to a beverage.
“Probiotics function in harmony with our immune system, effectively distinguishing allies from adversaries, and play a pivotal role in shielding us against harmful pathogens,” explains Vera Mogna, CEO of Probiotical. “The probiotic strains selected for MenaQ7 Protect naturally occur in the human body and work in concert with the immune system to fortify the body’s defenses. Through meticulous research, we have selected strains that are able to uniquely interact with the immune system, creating a targeted approach to stimulate and fortify our natural defenses. This pioneering collaboration aims to harness the synergistic potential of our premium probiotic strains and MenaQ7, offering a promising new avenue to support and bolster immune health.”
While MenaQ7 is well-known and proven as a supporter of bone and cardiovascular health, MenaQ7 Protect also marks the debut of Vitamin K2’s role as an immunomodulator. A MenaQ7 in-vitro research has shown it delivers an anti-inflammatory effect1 and reduces oxidative stress in human muscle cells2, important for immune response. Further, early but important evidence has shown that Vitamin K2 may suppress T-cell activation and proliferation, support lung health3, and protect against gut dysbiosis4, which helps optimize immune function.
“We are particularly excited about MenaQ7® Protect as it represents a foray into new areas for Gnosis, both in producing a finished product, but also shifting MenaQ7® into a new condition-specific arena,” said Philippe Caillat, Global Marketing Director with Gnosis by Lesaffre. “Immune health remains a shared common concern all year long and consumers consistently seek products that can optimize immune function continuously, while fitting into their lifestyles. MenaQ7® Protect perfectly fits this need while offering our customers a ready-to-market solution featuring our clinically proven MenaQ7® K2.”
MenaQ7 Protect was officially launched at this year’s SupplySide West to an excited and receptive crowd. The product is being produced by Probiotical, which will be fulfilling orders.
References
1 Pan M-H et al. J Med Food 2016 Jul;19(7):663-9.
2 Adubulut AC and Schurgers LJ. Bio Life Sci Forum. 2022,12(1).
3 Jespersen et al. ERJ Open Res. 2023 Aug 9;00208-2023
4 Lai Y et al. Front Immunol. 2022 Jan 5:12:791565.
